Where I see patients (1)
My reviews
5.0
Selected research
-
Circulating Immune Cell and Outcome Analysis from the Phase 2 Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.
Neuro-oncology
-
Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival.
Journal of the National Cancer Institute
Clinical trials
Feasibility of Individualized Therapy for Recurrent GBM
Feasibility of implementing a truly personalized tumor treatment drug regimen for patients with surgically resectable recurrent glioblastoma is defined as the percentage of patients who have successfully initiated therapy based on...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-2966